SCHEMBL1636835

SCHEMBL1636835

CC(C)(C)c1cccc(C(O)c2cccc(-c3ccccn3)c2)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.41
CETP P11597 1/20 0.40
ALOX5AP P20292 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FEN1 P39748 1/20 0.39
CTSL P07711 2/20 0.39
CTSK P43235 1/20 0.39
SCD O00767 1/20 0.38
ALOX5 P09917 1/20 0.37
GRM5 P41594 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
HRH3 Q9Y5N1 1/20 0.34
CTSA P10619 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12646948 0.86 CYP1A2 (0.44) FFAR1CETPCTSLCTSKALOX5
SCHEMBL1642760 0.84 FEN1 (0.43) ALOX5APLMNAHPGDALOX15TSHR
SCHEMBL1638313 0.80 LMNA (0.39) FFAR1ALOX5APLMNAHPGDALOX15
SCHEMBL1636931 0.78 FFAR1 (0.42) FFAR1CETPALOX5APFEN1CTSL
SCHEMBL1638990 0.78 FFAR1 (0.47) FFAR1LMNAHPGDCTSLCTSB
SCHEMBL1636933 0.78 FFAR1 (0.42) FFAR1CETPALOX5APFEN1CTSL
SCHEMBL1759281 0.75 TLR4 (0.42) FFAR1CETPALOX5APLMNASMN1; SMN2
SCHEMBL12076146 0.75 MGAM (0.41) FFAR1ALOX5APFEN1RXRARXRB
SCHEMBL1639166 0.73 CTSL (0.41) TSHRCTSLCTSKCTSBCTSS
SCHEMBL1638882 0.72 CTSL (0.41) TSHRCTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 FFAR1 480/4885CETP 1774/4885ALOX5AP 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.